Clearside Biomedical
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Clearside Biomedical generated cash of -$18,135,000, which is less than the previous year. Cash used in financing activities reached the amount of $414,000 last year. Net change in cash is therefore -$19,498,000.
Cash Flow
| 2014 | -9.12M | -140K | 15.62M |
|---|---|---|---|
| 2015 | -13.90M | -28K | 25.94M |
| 2016 | -22.70M | -49.14M | 86.39M |
| 2017 | -51.08M | 20.12M | 5.36M |
| 2018 | -79.2M | -3.76M | 81.77M |
| 2019 | -27.06M | 32.92M | 8.69M |
| 2020 | -13.12M | -55K | 7.86M |
| 2021 | -10.73M | 0 | 23.78M |
| 2022 | -13.36M | -246K | 31.33M |
| 2023 | -18.13M | -1.77M | 414K |
CLSD Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 48.41M | 30.69M | 17.64M | 22.95M | 8.40M | 9.58M | 34.82M | 20.28M | 8.26M | 1.90M |
Operating activities | ||||||||||
Net income | -32.48M | -32.94M | 376K | -18.21M | -30.77M | -82.81M | -58.97M | -25.88M | -17.63M | -10.18M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 67K | 145K | 178K | 180K | 211K | 189K | 182K | 65K | 60K | 33K |
Stock-based compensation expense | 4.20M | 4.88M | 5.05M | 3.6M | 4.61M | 0 | 3.36M | 1.31M | 705K | 427K |
| Deferred income tax benefit | 4.20M | 4.88M | 5.05M | 3.6M | 4.61M | 0 | 3.36M | 1.31M | 705K | 427K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 10.42M | -10.86M | 1.89M | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | -681K | -1.26M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 614K | 694K | 681K | -631K | -5.58M | -314K | 4.71M | 1.42M | 0 | 0 |
Cash generated by operating activities | -18.13M | -13.36M | -10.73M | -13.12M | -27.06M | -79.2M | -51.08M | -22.70M | -13.90M | -9.12M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | -80.14M | -48.11M | -54.48M | 0 | 0 |
Investments In Property Plant And Equipment | -1.77M | -246K | 0 | -55K | -25K | -88K | -306K | -3K | -32K | -140K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | -660K | -20.12M | 0 | 0 | 0 |
Cash generated by investing activities | -1.77M | -246K | 0 | -55K | 32.92M | -3.76M | 20.12M | -49.14M | -28K | -140K |
Financing activities | ||||||||||
Common Stock Issued | 1.66M | 566K | 23.78M | 11.95M | 13.64M | 79.56M | 5.05M | 84.83M | 12.74M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 308K | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | -5.34M | -5M | -8.3M | 0 | -6.33M | 5.97M | -125K |
Cash used in financing activities | 414K | 31.33M | 23.78M | 7.86M | 8.69M | 81.77M | 5.36M | 86.39M | 25.94M | 15.62M |
Net Change In Cash | -19.49M | 17.72M | 13.04M | -5.30M | 14.55M | -1.18M | -25.6M | 14.54M | 12.01M | 6.36M |
Cash at end of period | 28.92M | 48.41M | 30.69M | 17.64M | 22.95M | 8.40M | 9.22M | 34.82M | 20.28M | 8.26M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |